Pre Procedural Biomarkers Might Predict Recurrent Atrial Fibrillation After Catheter Ablation
Pre Procedural High Serum Visfatin and Tumor Necrosis Factors "Alpha" Might Predict Recurrent Atrial Fibrillation After Catheter Ablation
1 other identifier
interventional
117
1 country
1
Brief Summary
Evaluation of the predictive value of serum levels of adipocytokines and primary phase reactant for recurrent atrial fibrillation (RAF) after catheter ablation in 26 patients had persistent and 91 patients had paroxysmal AF. During 12-m follow-up, 41 patients had RAF (35%). Patients had RAF were significantly older, had significantly higher BMI, lower ejection fraction and wider maximal left atrial diameter (LAD). Serum hs-CRP, IL-6, TNF-α, visfatin, and adiponectin levels were significantly higher in patients developed. Elevated serum levels of TNF-α, visfatin and adiponectin are a significant positive predictors for RAF.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable atrial-fibrillation
Started Jul 2019
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2021
CompletedFirst Submitted
Initial submission to the registry
October 1, 2021
CompletedFirst Posted
Study publicly available on registry
November 10, 2021
CompletedNovember 10, 2021
November 1, 2021
2 years
October 1, 2021
November 5, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Recurrent Atrial Fibrillation
Recurrent Atrial Fibrillation after Catheter ablation
12 months
Study Arms (2)
Recurrent Atrial fibrillation
ACTIVE COMPARATORpatients developed Recurrent Atrial fibrillation catheter ablation
NO Recurrent Atrial fibrillation
ACTIVE COMPARATORpatients didn't develop Recurrent Atrial fibrillation catheter ablation
Interventions
ELISA Estimation of Serum visfatin and tumor necrosis factor-alpha
Eligibility Criteria
You may not qualify if:
- History of the presence of longstanding persistent or permanent AF,
- myocardial infarction, acute coronary syndrome (ACS),
- significant heart failure (NYHA3),
- dilated or hypertrophic cardiomyopathy,
- left ventricular ejection fraction (LVEF)\< 35%, congenital pathologies,
- significant valvular heart disease,
- pulmonary embolism,
- venous thrombosis,
- intracardiac thrombus or inability to take warfarin or other oral anticoagulants,
- hepatic or renal insufficiency,
- acute inflammatory states (sepsis, chronic obstructive pulmonary disease in acute phase),
- cancer,
- autoimmune pathologies.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Tanta Universitylead
Study Sites (1)
Tanta university
Tanta, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Amr El kassas, MD
Tanta University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- lecturer of Cardiology
Study Record Dates
First Submitted
October 1, 2021
First Posted
November 10, 2021
Study Start
July 1, 2019
Primary Completion
July 1, 2021
Study Completion
August 1, 2021
Last Updated
November 10, 2021
Record last verified: 2021-11